Gapping up
In reaction to strong earnings/guidance:
- XP +7.2%
Other news:
- IMV +79.3% (advances clinical development of a DPX-based vaccine candidate against COVID-19)
- VXRT +46.1% (entered into agreement with Emergent BioSolutions (EBS) for the development and manufacturing of oral coronavirus vaccine candidate)
- CANF +15.7% (confirming it is looking to partner on co-development of piclidenoson for coronavirus treatment ; will participate in the digital Bio-Europe Spring partnering conference from March 23 to 27, 2020)
- TGNA +12.7% (gets offer to be acquired and go private for $20/sh in cash)
- VXX +12.1% (trading higher with futures limit down)
- SAGE +7.6% (announces development plan for Zuranolone following FDA Breakthrough Therapy Guidance Meeting)
- VKTX +5.6% (authorizes $50 mln stock repurchase program)
- HOLX +4.9% (CEO says coronavirus test kits are being shipped out, with more to come)
- IDYA +4% (Pfizer and IDEAYA (IDYA) enter clinical trial collaboration and supply agreement to evaluate clinical combination of IDE196 and binimetinib in solid tumors harboring GNAQ or GNA11 hotspot mutations)
- NAT +1.9% ( to establish a share buy-back program)
- SPTN +1.1% (says it's seeing unprecedented sales volume since the onset of coronavirus)
Analyst comments:
- WUBA +1.1% (upgraded to Outperform from Neutral at Credit Suisse)